## Contents

| Edi | itors   | xiii                    |
|-----|---|-------------------------|
| Coı | ntributors  | xvii                    |
| Rev | viewers   | xxii                    |
| Abl | breviations   | xxiv                    |
| Acl | knowledgements  | XXX                     |
| Pre | face  | xxxi                    |
| 1   | Integration of Supportive and Palliative Care into Oncology Introduction What Do We Mean by Integration? ESMO Designated Centres of Integrated Oncology and Palliative Care Further Reading   | y 1<br>1<br>2<br>8<br>9 |
| 2   | Assessment of Symptoms and Needs Symptoms Prevalence and Intensity Depend on How They Are Assessed More Accurate Information Through Patient-reported   | 11<br>11                |
|     | Outcomes Validated Questionnaires Can Screen for Multiple Symptoms PROMs Can More Accurately Measure Severity of Symptoms and Toxicity Grade  | 12<br>12<br>13          |
|     | Routine Electronic PROMs Can Assess Symptom Burden Between Clinic Visits Beyond Symptoms – Assessment of Needs When Time is Short – Brief Multidimensional Screening Tools Valuable Screening Questions Assessing Coping, Social and Spiritual Resources is Paramount | 14<br>15<br>16<br>16    |
|     |   | -,                      |

|     | Assessments Must Lead to Action                            | 18 |
|-----|--|----|
|     | Further Reading  | 19 |
| 3   | Cancer-related Mental Health, Psychological, Spiritual     |    |
|     | and Cultural Issues  | 21 |
|     | Mental Health, Psychological and Emotional Issues Related  |    |
|     | to Cancer - Treating the Patient in an Integrated and      |    |
|     | Holistic Manner  | 21 |
|     | Spiritual and Cultural Issues Related to Cancer            | 22 |
|     | Prevalence of Mental Health and Psychological Issues       |    |
|     | Related to Cancer  | 22 |
|     | Psychosocial Understanding of a Cancer Diagnosis           |    |
|     | and Treatment  | 23 |
|     | Special Aspects of Mental Health and Psychosocial Issues   |    |
|     | in Cancer  | 24 |
|     | Conclusion   | 28 |
|     | Further Reading  | 28 |
| 4   | <b>Communication with Cancer Patients</b>                  | 30 |
|     | The Importance and Benefits of Effective Communication     |    |
|     | in the Cancer Setting                                      | 30 |
|     | Challenging Situations                                     | 32 |
|     | Further Reading  | 38 |
| 5   | Predicting Prognosis                                       | 39 |
|     | The Importance of Predicting Prognosis                     | 39 |
|     | Predicting Prognosis in the Era of Immunotherapy           | 41 |
|     | The Reasons Why Some Clinicians are Better Prognosticators |    |
|     | Than Others  | 42 |
|     | Tools to Support Predicting Prognosis                      | 43 |
|     | The Importance of Communication                            | 46 |
|     | Key Messages   | 46 |
|     | Further Reading  | 47 |
| 6   | Cancer- and Treatment-related Symptoms                     | 49 |
| 6.1 | Toxicities of Immunotherapy and Targeted Therapy           | 50 |
|     | The Mechanism of Action of Immune Checkpoints              | 50 |

|     | The Mechanisms of Action of Targeted Therapies                 | 51 |
|-----|--|----|
|     | Toxicities of ICIs and Their Management                        | 52 |
|     | Toxicities of Targeted Therapies and Their Management          | 56 |
|     | Conclusion   | 59 |
|     | Further Reading  | 59 |
| 6.2 | Radiotherapy-induced Symptoms                                  | 62 |
|     | Radiotherapy-induced Nausea and Vomiting                       | 63 |
|     | Neurotoxicity  | 63 |
|     | Lung Toxicity  | 64 |
|     | Gastrointestinal Toxicity                                      | 66 |
|     | Skin Toxicity  | 68 |
|     | Further Reading  | 70 |
| 6.3 | <b>Gastrointestinal Problems</b>                               | 72 |
|     | Introduction: The Prevalence of Gastrointestinal Complications |    |
|     | in Cancer Patients and the Impact on their Quality of Life     | 72 |
|     | 6.3.1 Malignant Bowel Obstruction                              | 73 |
|     | Incidence  | 73 |
|     | Causes   | 73 |
|     | Clinical Features  | 73 |
|     | Diagnosis  | 73 |
|     | Principles of Treatment  | 74 |
|     | Further Reading  | 77 |
|     | 6.3.2 Constipation   | 78 |
|     | Incidence  | 78 |
|     | Causes   | 78 |
|     | Grading  | 79 |
|     | Prevention, Diagnosis and Management                           | 79 |
|     | Further Reading  | 80 |
|     | 6.3.3 Diarrhoea  | 81 |
|     | Most Frequent Causes and Incidence                             | 81 |
|     | Grading  | 82 |
|     | Principles of Treatment  | 82 |
|     | Further Reading  | 84 |
|     |  |    |

| 6.3.4 Cachexia and Nutrition                               | 85  |
|--|-----|
| Incidence, Pathophysiology and Clinical Impact of Cachexia | 85  |
| Definition of Cachexia                                     | 85  |
| Early Detection and Assessment of Cachexia                 | 86  |
| Treatment of Cachexia                                      | 86  |
| Further Reading  | 87  |
| 6.3.5 Mucositis  | 88  |
| Incidence  | 88  |
| Clinical Presentation                                      | 89  |
| Grading  | 89  |
| Principles of Treatment                                    | 90  |
| Further Reading  | 90  |
| 6.3.6 Chemotherapy/Radiotherapy-related Nausea             |     |
| and Vomiting   | 91  |
| Incidence  | 91  |
| Causes   | 91  |
| Grading  | 92  |
| Principles of Treatment                                    | 92  |
| Further Reading  | 93  |
| 6.3.7 Tumour-related Nausea and Vomiting in                |     |
| Advanced Cancer  | 94  |
| Incidence  | 94  |
| Causes   | 94  |
| Assessment   | 94  |
| Principles of Treatment                                    | 96  |
| Further Reading  | 97  |
| 6.3.8 Malignant Ascites                                    | 98  |
| Definition   | 98  |
| Aetiology  | 98  |
| Clinical Presentation                                      | 98  |
| Diagnosis  | 98  |
| Treatment  | 99  |
| Further Reading  | 100 |

| 6.4        | Respiratory Problems                             | 101 |
|------------|--|-----|
|            | Introduction                                     | 101 |
|            | Dyspnoea   | 101 |
|            | Cough  | 106 |
|            | Haemoptysis                                      | 109 |
|            | Further Reading                                  | 110 |
| 6.5        | Neurological Complications                       | 112 |
|            | Introduction                                     | 112 |
|            | 6.5.1 Delirium                                   | 113 |
|            | Further Reading                                  | 114 |
|            | 6.5.2 Seizures                                   | 115 |
|            | Further Reading                                  | 116 |
|            | 6.5.3 Encephalopathy                             | 117 |
|            | Further Reading                                  | 118 |
|            | 6.5.4 Brain Metastasis                           | 120 |
|            | Further Reading                                  | 121 |
|            | 6.5.5 Leptomeningeal Metastases in Solid Tumours | 123 |
|            | Further Reading                                  | 125 |
|            | 6.5.6 Spinal Cord Compression                    | 126 |
|            | Further Reading                                  | 127 |
|            | 6.5.7 Peripheral Neuropathy                      | 128 |
|            | Further Reading                                  | 129 |
| 6.6        | Psychiatric Problems in Cancer Patients          | 130 |
|            | Prevalence                                       | 130 |
|            | Assessment                                       | 131 |
|            | Management of Specific Psychiatric Disorders     | 132 |
|            | Conclusion                                       | 137 |
|            | Further Reading                                  | 138 |
| <b>6.7</b> | Cancer Pain                                      | 140 |
|            | Prevalence and Aetiology of Cancer Pain          | 140 |
|            | Assessment and Classification of Cancer Pain     | 140 |
|            | Management of Cancer Pain                        | 142 |
|            | Further Reading                                  | 146 |

| 6.8 | Haematological Complications                                  | 148 |
|-----|---|-----|
|     | Introduction: Haematological Complications in Cancer Patients | 148 |
|     | 6.8.1 Anaemia   | 149 |
|     | Background and Evaluation                                     | 149 |
|     | Management  | 149 |
|     | Further Reading   | 151 |
|     | 6.8.2 Febrile Neutropaenia                                    | 152 |
|     | Definition of Febrile Neutropaenia                            | 152 |
|     | Incidence, Morbidity, Mortality and Microorganisms            | 152 |
|     | Chemoprophylaxis  | 153 |
|     | Indications for Primary Prophylaxis of FN with G-CSF          | 153 |
|     | Dose Schedule, Route of Application of G-CSF                  |     |
|     | and Pegfilgrastim   | 153 |
|     | Management of FN: Patient Education and Local Policies        | 153 |
|     | Further Reading   | 154 |
|     | 6.8.3 Thrombocytopaenia                                       | 155 |
|     | Incidence   | 155 |
|     | Grades  | 155 |
|     | Clinical Features   | 156 |
|     | Principles of Management                                      | 156 |
|     | Prevention of Bleeding  | 157 |
|     | Chemotherapy-induced Thrombocytopaenia                        | 157 |
|     | Further Reading   | 157 |
|     | 6.8.4 Bleeding  | 159 |
|     | Background  | 159 |
|     | Evaluation  | 159 |
|     | Disseminated Intravascular Coagulation                        | 159 |
|     | Vitamin K Antagonists, Heparin and Direct Oral                |     |
|     | Anticoagulants  | 160 |
|     | Specific Bleeding Settings                                    | 161 |
|     | Further Reading   | 161 |
|     | 6.8.5 Thromboembolic Events                                   | 162 |
|     | Background and Clinical Consequences                          | 162 |
|     | Pathophysiology   | 162 |

|      | Incidence   | 163 |
|------|---|-----|
|      | Assessment of Thrombotic Risk                             | 163 |
|      | Principles of Thromboprophylaxis                          | 163 |
|      | Principles of Treatment                                   | 164 |
|      | Conclusion  | 166 |
|      | Further Reading   | 166 |
| 6.9  | <b>Metabolic Complications of Cancer</b>                  | 168 |
|      | Hypercalcaemia  | 168 |
|      | Syndrome of Inappropriate Antidiuretic Hormone            | 171 |
|      | Further Reading   | 174 |
| 6.10 | Fatigue   | 175 |
|      | Pharmacological Treatments                                | 177 |
|      | Non-pharmacological Interventions                         | 178 |
|      | Mind-Body Interventions                                   | 179 |
|      | Further Reading   | 180 |
| 7    | Care of the Dying Patient                                 | 182 |
|      | Identifying That Death is Close                           | 182 |
|      | Advance Directives  | 183 |
|      | Where Should the Patient be Cared For                     | 183 |
|      | Patient Care  | 184 |
|      | Anticipatory Care Planning for Emergencies                | 188 |
|      | Using Sedation for Refractory Distress                    | 189 |
|      | Family Wellbeing  | 191 |
|      | When Death Occurs   | 193 |
|      | After a Patient Death                                     | 194 |
|      | Conclusion  | 194 |
|      | Further Reading   | 195 |
| 8    | Rehabilitation in Cancer - Role of Exercise and Nutrition | 196 |
|      | Safeguarding Exercise Capacity During and                 |     |
|      | After Cancer Treatment                                    | 196 |
|      | Nutrition During Cancer Treatment and Follow-up           | 201 |
|      | Lifestyle Changes During Cancer Treatment and Follow-up   | 202 |
|      | Further Reading   | 204 |

| 9   | Living With and Beyond Cancer                          | 207 |
|-----|--|-----|
|     | Reproductive Issues                                    | 207 |
|     | Cognitive Impairment After Cancer Treatment            | 211 |
|     | Survivor Care Plans                                    | 212 |
|     | Further Reading  | 214 |
| 10  | <b>Ethics in Supportive and Palliative Care</b>        | 216 |
|     | Respect for Autonomy and Consent                       | 217 |
|     | Withholding or Withdrawing Life-prolonging Treatment   | 219 |
|     | Supporting Healthcare Professionals to Manage Patients |     |
|     | and Their Families at the End of Life                  | 219 |
|     | Further Reading  | 220 |
| 11  | Research in Supportive and Palliative Care             | 221 |
|     | Ongoing Research                                       | 222 |
|     | Areas of Greatest Need                                 | 223 |
|     | Further Reading  | 225 |
| Ind | Index  |     |



## Does this Table of Contents interest you? Would you like to read more?

If you are an ESMO Member, simply log in to your account to <u>download the complete book</u> along with over 20 other titles on a broad range of topics - all of them written to assist you in your daily practice.

If not an ESMO Member, then consider joining!

ESMO Members belong to a global community of over 25,000 oncology professionals. Membership provides you many other benefits, including:

- Full access to ESMO educational and scientific resources, all centralised on our portal OncologyPRO
- An online subscription to Annals of Oncology
- A wide range of exclusive courses and learning opportunities for every stage of your career
- Reduced registration fees for ESMO meetings

Discover more and join ESMO today!

